1 April 2002, vol. 8, no. 2, pp. 142-154(13)
Weiner HL; Cohen JA
 Multiple Sclerosis Center, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Longwood Avenue, Boston, Massachusetts 02115, USA
 Clinic Foundation, The Mellen Center U10, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
Cyclophosphamide is an alkylating agent used to treat malignancies and immune-mediated inflammatory non-malignant processes such as lupus nephritis and immune-mediated neuropathies.
It has been studied as a treatment for multiple sclerosis (MS) for the past 30 years and is used by physicians in selected cases of progressive or worsening MS.
Review of published reports suggests that it is efficacious in cases of worsening MS that have an inflammatory component as evidenced by relapses and/or gadolinium (Gd)-enhancing lesions on magnetic resonance imaging (MRI) or in patients in earlier stages of disease where inflammation predominates over degenerative processes in the central nervous system (CNS).
There is no evidence of efficacy in primary progressive MS or later stages of secondary progressive MS.
Although a general immunosuppressant that affects both T- and B-cell function, cyclophosphamide has selective immune effects in MS by suppressing IL-12 and Th1-type responses and enhancing Th2/Th3 responses (IL-4, IL-10, TGF-beta; eosinophils in peripheral blood).
Side effects include nausea, alopecia, infertility, bladder toxicity and risk of malignancy.
The most commonly used regimens involve every 4- to 8-week outpatient IV pulse therapy given with or without corticosteroids and are usually well-tolerated by patients.
Cyclophosphamide is currently used in patients whose disease is not
controlled by beta-interferon or glatiramer acetate and those with rapidly
© 2002 ingenta